By Dr. Samir Kulkarni, Ph.D. Pfizer, Groton, CT The improved development and scaleup of Nirmatrelvir (the active 3CL protease inhibitor in PaxlovidTM) with efficient chemical synthesis led to FDA...
Dr. Samir Kulkarni is currently working as Senior Principal Scientist in Pharmaceutical Sciences, Pfizer Chemical R＆D working in Groton, CT. He earned his Ph.D. in Chemical Engineering at Delft...
Cheng received his BS in Chemistry at Xiamen University in 1984 and subsequently continued his Ph.D study at the Ohio State University from 1985-1990. He single handedly completed the...
By Scott Shultz, Ph.D. Department of Analytical Research and Development, Merck & Co., Inc., Rahway, NJ, USA The role of the crystalline solid phase is often an enabling feature...
Scott Shultz has over 20 years of pharmaceutical development experience at Merck in the process and analytical development areas. Since 2008 Scott has led numerous efforts in the materials...
By Cheng Yi Chen, Ph.D. Chemical Processing R&D, Mirati Therapeutics, San Diego, CA 92130, USA chenc@mirati.com A new approach to stereopure atropisomeric molecules is enabled by a continuous flow-crystallization...
By Fredrik Nordstrom, Ph.D. Material and Analytical Sciences, Boehringer-Ingelheim, Ridgefield, CT, 06877 fredrik.nordstrom@boehringer-ingelheim.com The decision for selecting and optimizing the synthetic route of a drug candidate is to a...
Dr. Fredrik Nordstrom leads a solid state and crystallization group within the Material and Analytical Science department at Boehringer-Ingelheim, Ridgefield, CT. The Solid State Chemistry group is responsible for...
